Table 2. Detailed include numbers of samples in different biomarkers research.
| Study | Biomarkers | NC | MCI | AD | Total |
| Genotype data | Total included | 211 | 346 | 162 | 719 |
| Neuropsychological test | CDRSB | 210 | 346 | 162 | 718 |
| ADAS11 | 211 | 345 | 162 | 718 | |
| ADAS13 | 211 | 342 | 158 | 711 | |
| MMSE | 211 | 345 | 162 | 718 | |
| RAVLT | 210 | 345 | 161 | 716 | |
| FAQ | 211 | 344 | 162 | 717 | |
| CSF biomarkers | Tau/Aβ1-45/P-tau | 108 | 176 | 88 | 372 |
| MRI | Regional brain volume | 208 | 343 | 156 | 707 |
| Hippocampus volume | 193 | 293 | 133 | 619 | |
| PET | CMRgl on FDG-PET | 96 | 179 | 85 | 360 |
Abbreviations: NC, normal control; MCI, mild cognitive impairment; AD, Alzheimer's disease; n, number; CDRSB, Clinical Dementia Rating scale sum of boxes; ADAS, Alzheimer's disease Assessment Scale; MMSE, Mini-Mental State Exam; RAVLT, Rey Auditory Verbal Learning Test; FAQ, Functional Activities Questionnaire; CMRgl, the regional cerebral metabolic rate for glucose; PET, fluorodeoxyglucose positron emission tomography.